跳转至内容
Merck

N1200000

炔诺酮

European Pharmacopoeia (EP) Reference Standard

别名:

17α-乙炔基-19-去甲睾酮, 17-羟基-19-去甲-17α-孕甾-4-烯-20-炔基-3-酮, 17α-乙炔基-17β-羟基-19-去甲-4-雄甾烯-3-酮, 19-去甲-17α-乙炔基-4-雄甾烯-17β-醇-3-酮, 去甲基脱氢羟孕酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H26O2
CAS号:
分子量:
298.42
Beilstein:
1915671
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

norethisterone

製造商/商標名

EDQM

mp

205-206 °C (lit.)

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI 密鑰

VIKNJXKGJWUCNN-XGXHKTLJSA-N

基因資訊

human ... PGR(5241)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Norethisterone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

炔诺酮是用于抑制细胞溶质磺基转移酶类 (SULT) 的口服避孕药。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardEnvironment

訊號詞

Danger

危險分類

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 3

1 of 3

Derin J Cobia et al.
Schizophrenia research, 139(1-3), 1-6 (2012-06-01)
Cortical abnormalities are considered a neurobiological characteristic of schizophrenia. However, the pattern of such deficits as they progress over the illness remains poorly understood. The goal of this project was to assess the progression of cortical thinning in frontal and
Patricia M LoRusso et al.
Cancer chemotherapy and pharmacology, 71(1), 193-202 (2012-10-16)
Vismodegib, a first-in-class oral hedgehog pathway inhibitor, is an effective treatment for advanced basal cell carcinoma. Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI
Chelsea B Polis et al.
The Lancet. Infectious diseases, 13(9), 797-808 (2013-07-23)
Whether or not the use of hormonal contraception affects risk of HIV acquisition is an important question for public health. We did a systematic review, searching PubMed and Embase, aiming to explore the possibility of an association between various forms
H F Taitel et al.
International journal of fertility and menopausal studies, 40(4), 207-223 (1995-07-01)
Norethindrone is utilized for numerous noncontraceptive therapies, especially during the menopause. Through an analysis of the literature we have described the pharmacological profile of norethindrone and the potential therapeutic implications of low-dose therapies, with an emphasis on endometrial pathology, climacteric
Karl van den Broeck et al.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 17(5), 321-328 (2012-09-15)
Ferdinand Peeters, a practising gynaecologist from Turnhout, near Antwerp (Belgium), had a pivotal role in the development of a practical and viable modality of oral contraception, striking the balance between efficacy and an acceptably low incidence and severity of side

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门